FDA Warns of Dosing Errors and Adverse Events Linked to Compounded Semaglutide

FDA Alerts Providers to Adverse Events and Dosing Errors Associated With Compounded Semaglutide

The U.S. Food and Drug Administration has alerted health care providers, compounding facilities, and patients to adverse events associated with compounded injectable semaglutide. Reports include hospitalizations for severe nausea, vomiting, dehydration, gastroenteritis, and overdoses linked to dosing errors with multi-dose vials [1][2]. Many compounded products contain unapproved semaglutide sodium or acetate salt forms rather than the base form evaluated in approved products such as Ozempic and Wegovy [1]. Following resolution of shortages for certain approved injectable semaglutide presentations as of October 2024, the FDA stated that compounding of those products must cease except in limited cases meeting 503A or 503B requirements [4].

Adverse Events Reported

The FDA has received voluntary adverse event reports tied to compounded semaglutide [1]. These reports describe severe gastrointestinal effects that led to hospitalization in some instances. Dosing errors occurred when syringe markings on multi-dose vials were misread, resulting in administration of five to 20 times the intended dose [2].

Differences Between Approved and Compounded Forms

Approved semaglutide products contain the base form of the molecule, which completed FDA review for safety, efficacy, and manufacturing quality. The FDA reported that many compounded versions instead use semaglutide sodium salt or acetate salt forms that have not been reviewed for safety, efficacy, or quality [1][2]. MedlinePlus information on semaglutide injection addresses only the approved formulation [3].

Regulatory Requirements for Compounding

Sections 503A and 503B of federal law permit compounding of semaglutide only when an FDA-approved product cannot meet a patient’s documented clinical need and all quality, documentation, and labeling standards are followed [1]. The FDA determined that shortages for certain approved injectable semaglutide presentations have resolved [4]. In its update the agency stated that large-scale compounding of these specific products must stop [4].

What this means

The update indicates that adverse event reports have been received in association with compounded semaglutide, including serious gastrointestinal outcomes and overdoses from dosing errors. The reports highlight differences in formulation between the FDA-reviewed base form and the unapproved salt forms used in some compounded products. Resolution of the specified shortages narrows the regulatory conditions under which compounding remains permissible under federal rules.

Limitations

These findings rely on voluntary adverse-event reporting, which likely underrepresents total incidence. No new randomized clinical trial data on compounded products is presented. Guidance is U.S.-specific and does not address international compounding standards or long-term outcomes.